Abstract:AIM:The purpose of this study was to investigate the effect of CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in liver transplant recipients and donors on tacrolimus concentrations in the early stages after liver transplantation. METHODS:One hundred and thirty-eight liver transplant recipients and matched donors were genotyped for CYP3A7 (rs10211 and rs2257401), CYP3A4 (rs4646437 and rs2242480), and CYP3A5*3 (rs776746) polymorphisms. The relationships between dose-adjusted trough concentrations (C0/D) of tacrolimus and corresponding genotypes were investigated. RESULTS:Recipient CYP3A polymorphisms were associated with tacrolimus concentrations. The CYP3A7 rs10211 AA carriers (186.2 vs 90.5, p < 0.001), CYP3A4 rs4646437 CC carriers (184.0 vs 88.8, p < 0.001), CYP3A4*1G rs2242480 CC carriers (189.8 vs 99.7, p < 0.001), and CYP3A5*3 rs776746 GG carriers (197.3 vs 86.0, p < 0.001) had an almost twofold increase in the tacrolimus C0/D compared to that of the non-carriers. We further investigated the effect of the combination of recipient (intestinal) and donor (hepatic) genotypes on tacrolimus concentrations. Regardless of the genotype of the matched donor, CYP3A7 rs10211, CYP3A4*1G (rs2242480), and CYP3A5*3 (rs776746) polymorphisms of recipients could affect tacrolimus concentrations. For the CYP3A4 rs4646437 polymorphisms, when the donor carried CYP3A4 rs4646437 CC, the recipient CYP3A4 rs4646437 polymorphism was associated with the C0/D of tacrolimus, and when the donor carried CYP3A4 rs4646437 CT/TT genotype, the recipient CYP3A4 rs4646437 polymorphism also affected on tacrolimus C0/D, although the effect was not significant. CONCLUSION:The large inter-individual variation in tacrolimus concentrations in the early stages after liver transplantation is influenced by genetic polymorphisms of CYP3A7, CYP3A4, and CYP3A5. Recipient (intestinal) CYP3A7, CYP3A4, and CYP3A5 polymorphisms seem to contribute more to such variation than donors. Therefore, the detection of CYP3A polymorphisms in recipients could help to predict the tacrolimus starting dose in the early stages after liver transplantation.

Association of Donor Cytochrome P450 3A Family Polypeptide 5 and Interleulin-18 Polymorphisms with the Individual Dosage Regimen of Tacrolimns in Chinese Liver Transplantation Recipients

Combined Effect of Donor Cytochrome P450 3A Family Polypeptide 5 and Recipient Cytochrome P450 3A Family Polypeptide 4 Polymorphisms on the Individual Dosage Regimen of Tacrolimus in Chinese Liver Transplant Patients

Association of CYP3A5 and IL-10 Polymorphisms with the Individual Dosage Regimen of Tacrolimus in Lung Transplantation Recipients

Association of CYP3A5 and C5 Polymorphisms with the Individual Dosage Regimen of Tacrolimus in Chinese Liver Transplantation Recipients During the Early Post-Transplantation Period

Polymorphisms of Tumor Necrosis Factor-Α, Interleukin-10, Cytochrome P450 3A5 and ABCB1 in Chinese Liver Transplant Patients Treated with Immunosuppressant Tacrolimus

Effect of CYP3A5 polymorphism on the concentration /dose ratio of tacrolimus in liver transplant recipients

The Pharmacokinetic Study of Tacrolimus and Wuzhi Capsule in Chinese Liver Transplant Patients

Effect of CYP3A5 and MDR1 Gene Polymorphism on Concentration/Dose Ratios of Tacrolimus in Chinese Liver Transplant Patients

Effect of cytochrome P450 3A5 (CYP3A5) genotype on tacrolimus dose requirement in renal transplant patients

ABCB1 Haplotype Influences the Sirolimus Dose Requirements in Chinese Renal Transplant Recipients.

Impact of Interleukin-10 Gene Polymorphisms on Tacrolimus Dosing Requirements in Chinese Liver Transplant Patients During the Early Posttransplantation Period.

Influence of IL-18 and IL-10 Polymorphisms on Tacrolimus Elimination in Chinese Lung Transplant Patients

Donor Il-18 Rs5744247 Polymorphism As A New Biomarker Of Tacrolimus Elimination In Chinese Liver Transplant Patients During The Early Post-Transplantation Period: Results From Two Cohort Studies

Influence Of Cyp3a5 Gene Polymorphisms Of Donor Rather Than Recipient To Tacrolimus Individual Dose Requirement In Liver Transplantation

IL-3 and CTLA4 gene polymorphisms may influence the tacrolimus dose requirement in Chinese kidney transplant recipients

Population Pharmacokinetics of Tacrolimus and CYP3A5, MDR1 and IL-10 Polymorphisms in Adult Liver Transplant Patients

CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation.

Influence of CYP3A5 polymorphism on tacrolimus blood concentrations in renal transplant patients

Cyp3a4/5 Polymorphisms Affect The Blood Level Of Cyclosporine And Tacrolimus In Chinese Renal Transplant Recipients

Tacrolimus Dose Requirement In Relation To Donor And Recipient Abcb1 And Cyp3a5 Gene Polymorphisms In Chinese Liver Transplant Patients

CYP3A5 Rather Than MDR1 Gene Polymorphism of Recipient is Related to Tacrolimus Individual Dose Requirement in Chinese Liver Transplant Patients